This disclosure describes biosynthesized compounds including anhydromevalonolactone and -methyl--valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce -methyl--valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

This disclosure describes biosynthesized compounds including anhydromevalonolactone and -methyl--valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce -methyl--valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).

The present invention relates to the use of compounds of the formula (I) for the care, preservation or improvement of the general condition or appearance of the skin or hair, and to preparations comprising compounds of the formula (I).

The present invention relates to a novel salicylic acid derivative, a method for preparing the same, and a cosmetic composition for whitening having the same. The compound exhibits a skin whitening effect by acting on tyrosinase, which is a melanin producing enzyme, to inhibit the production of melanin, and exhibits an improved skin whitening effect compared with kojic acid, alkyl salicylic acid, or alkoxy salicylic acid, which is previously known as a skin whitening agent. Therefore, the compound can be variously applied to cosmetics, preparations for external use, and the like.

The present invention relates to a process for preparation of intermediates (Z,2E)-5-hydroxy-2-methoxyimino-N-methyl-pent-3-enamides from 4-substituted 5-meth-oxyimino-2H-pyran-6-ones and their processing for example to (Z)-5-cyclyloxy-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl amides. The invention also relates to a process for preparation of 4-substituted 5-imino-2H-pyran-6-ones and to novel intermediates for the preparation of fungicidal (Z)-5-cyclyloxy-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl amides.

The present invention relates to a process for preparation of intermediates (Z,2E)-5-hydroxy-2-methoxyimino-N-methyl-pent-3-enamides from 4-substituted 5-meth-oxyimino-2H-pyran-6-ones and their processing for example to (Z)-5-cyclyloxy-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl amides. The invention also relates to a process for preparation of 4-substituted 5-imino-2H-pyran-6-ones and to novel intermediates for the preparation of fungicidal (Z)-5-cyclyloxy-2-[(E)-methoxyimino]-3-methyl-pent-3-enic acid methyl amides.

Small molecule stimulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing cancer. Also provided are methods for stimulating SRC family proteins in a cell.

The present invention relates to a novel compound having an effect of inhibiting platelet aggregation and a salt thereof and, more specifically, to: a novel platelet aggregation inhibitor specifically inhibiting shear stress-induced platelet aggregation; a pharmaceutical composition containing the same as an active ingredient; and a preparation method therefor.

The present invention relates to a novel compound having an effect of inhibiting platelet aggregation and a salt thereof and, more specifically, to: a novel platelet aggregation inhibitor specifically inhibiting shear stress-induced platelet aggregation; a pharmaceutical composition containing the same as an active ingredient; and a preparation method therefor.